Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 125 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transcatheter Valve Replacement Clear all
Active, not recruiting Not applicable Interventional

Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

NCT06680427
View directory record Official record
Conditions
Aortic Stenosis Symptomatic
Interventions
Siegel Transcatheter Aortic Valve (TAVR)
Device
Lead sponsor
MiRus
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Recruiting No phase listed Observational

Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR

NCT07309029
View directory record Official record
Conditions
Severe Aortic Stenosis, Cardiogenic Shock, Cardiogenic Shock, ECMO, Trans-catheter Aortic Valve Implantation
Interventions
Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation (LAVA-ECMO)
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Detroit, Michigan • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

NCT04889872
View directory record Official record
Conditions
Aortic Stenosis, Calcific, Aortic Valve Stenosis
Interventions
SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
65 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2037
U.S. locations
65
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Completed No phase listed Observational

COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction

NCT02987387
View directory record Official record
Conditions
Pulmonary Valve Insufficiency, Pulmonary Valve Stenosis, Heart Defects, Congenital, Congenital Abnormalities, Cardiovascular Diseases, Heart Diseases
Interventions
SAPIEN XT THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure

NCT07205068
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Shockwave M5 IVL Catheter, Modified Seldinger Technique
Device · Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

MRI in Transcatheter Aortic Valve Replacement Patients

NCT05603026
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Self-expanding valve (Medtronic Evolut FX), Balloon-expanding valve (Edwards Sapien 3 Ultra RESILIA)
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 105 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Completed Not applicable Interventional Results available

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

NCT04149535
View directory record Official record
Conditions
Stroke
Interventions
Sentinel® Cerebral Protection System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
41
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 8, 2026, 11:48 AM EDT
Completed No phase listed Observational

Paravalvular Leak for Transcatheter Valve Replacement

NCT02079129
View directory record Official record
Conditions
Paravalvular Leak, Transcatheter Valve Replacement
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 8, 2026, 11:48 AM EDT
Completed No phase listed Observational Results available

TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR

NCT05804240
View directory record Official record
Conditions
Right Ventricular Dysfunction
Interventions
3D TEE RVEF
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Completed Not applicable Interventional Results available

This Study Will Evaluate the Safety and Potential Complications of Dual ProGlide vs Single ProGlide and Angioseal for Common Femoral Arteriotomy Closure Following Transcatheter Aortic Valve Replacement

NCT06983938
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement, Closure Technique
Interventions
Double Perclose Proglide, Single Perclose Proglide plus Angioseal
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Completed No phase listed Observational

Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)

NCT04827238
View directory record Official record
Conditions
Aortic Stenosis, Aortic Valve Stenosis
Interventions
Standardized Invasive Hemodynamics
Diagnostic Test
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Tucson, Arizona • Boca Raton, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR

NCT05295628
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement
Interventions
EMBLOK™ Embolic Protection System ("EMBLOK EPS"), SENTINEL™ Cerebral Protection System
Device
Lead sponsor
Emblok, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Chandler, Arizona • Orange, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Withdrawn Not applicable Interventional

U.S. Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

NCT06069661
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Aortic Stenosis
Device
Lead sponsor
EnCompass Technologies, Inc.
Industry
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 8, 2026, 11:48 AM EDT
Completed No phase listed Observational Results available

Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement

NCT03117296
View directory record Official record
Conditions
Transcatheter Aortic Valve Implantation
Interventions
Post procedure daily PT and OT, PT post procedure, OT post procedure, Routine PT or OT
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 8, 2026, 11:48 AM EDT
Active, not recruiting Not applicable Interventional

SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

NCT03230747
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Disease
Interventions
Edwards SAPIEN M3 System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Completed Not applicable Interventional Results available

WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

NCT03173534
View directory record Official record
Conditions
Atrial Fibrillation, Aortic Valve Stenosis
Interventions
WATCHMAN, TAVR
Device
Lead sponsor
samir kapadia
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
32
States / cities
Phoenix, Arizona • Burlingame, California • Santa Barbara, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 8, 2026, 11:48 AM EDT
Not yet recruiting Not applicable Interventional

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

NCT07806149
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions
SESAME Procedure
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Completed Not applicable Interventional

Conduction Disease After Transcatheter Aortic Valve Replacement

NCT04489095
View directory record Official record
Conditions
Aortic Stenosis, Heart Block, Aortic Insufficiency
Interventions
Electrophysiology Study
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Sep 8, 2026, 11:48 AM EDT
Active, not recruiting Not applicable Interventional Results available

PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

NCT02675114
View directory record Official record
Conditions
Aortic Stenosis
Interventions
SAVR, SAPIEN 3 THV
Procedure · Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burlingame, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Recruiting Phase 4 Interventional

Patient Quality of Recovery After TAVR With Different Sedation Regimens

NCT07556523
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement (TAVR), Aortic Valve Stenosis
Interventions
Propofol, Dexmedetomidine, Midazolam, Fentanyl
Drug
Lead sponsor
David Lyubashevsky
Other
Eligibility
18 Years to 90 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Active, not recruiting Not applicable Interventional

Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)

NCT05541679
View directory record Official record
Conditions
Complete Heart Block, High Degree Second Degree Atrioventricular Block, Pacemaker-Induced Cardiomyopathy, Aortic Valve Stenosis
Interventions
Right ventricular septal pacing followed by left bundle branch area pacing, Left bundle branch area pacing followed by right ventricular septal pacing
Device
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Overland Park, Kansas • Ridgewood, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 8, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)

NCT05848284
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Interventions
VDyne Transcatheter Tricuspid Valve Replacement System
Device
Lead sponsor
VDyne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Detriot, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 8, 2026, 11:48 AM EDT
Withdrawn Not applicable Interventional

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

NCT05409378
View directory record Official record
Conditions
Aortic Regurgitation
Interventions
The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
Device
Lead sponsor
HLT Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 8, 2026, 11:48 AM EDT
Completed Phase 4 Interventional Results available

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

NCT02486367
View directory record Official record
Conditions
Aortic Stenosis, Inflammation, Thrombosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 8, 2026, 11:48 AM EDT